PEMF for
Menstrual Pain.

June 2026 · 9 min read · Women's Health

The Scale of Dysmenorrhea in the Philippines

Primary dysmenorrhea — painful menstruation without an identifiable pelvic pathology — affects an estimated 72% of Filipino women aged 15–45 (approximately 15 million women). Of these, 15% experience pain severe enough to cause school or work absence each month. Current treatment remains heavily pharmacological: NSAIDs (ibuprofen, mefenamic acid) are the first-line standard, with hormonal contraceptives used for more severe cases. Both carry significant disadvantages — GI adverse effects in 20–30% of NSAID users, and contraceptive hormones that are inappropriate for women planning pregnancy or those with hormonal sensitivities. PEMF offers a non-pharmacological, mechanism-targeted alternative with randomized trial support.

Primary vs. Secondary Dysmenorrhea

• Primary dysmenorrhea: pain without identifiable pelvic pathology. Caused by excessive prostaglandin PGF2α and PGE2 production in the uterine endometrium, driving uterine smooth muscle contractions that exceed the ischemic threshold, producing cramping pain of VAS 6–9/10.
• Secondary dysmenorrhea: pain caused by an identifiable condition (endometriosis, fibroids, adenomyosis, pelvic inflammatory disease). PEMF addresses both categories differently — for secondary dysmenorrhea, it provides symptomatic relief while the underlying condition is managed surgically or medically.

The Mechanism: How PEMF Interrupts Menstrual Pain

PEMF acts on three simultaneous pathways:

1. Prostaglandin Suppression — PEMF fields suppress cyclooxygenase-2 (COX-2) expression in uterine endometrial cells, reducing the production of PGF2α and PGE2, the primary contractile triggers of dysmenorrheal pain.
2. Smooth Muscle Relaxation — By modulating calcium ion flux across uterine smooth muscle cell membranes, PEMF reduces the amplitude and frequency of uterine contractions, directly reducing ischemic pain.
3. Central Neuromodulation — PEMF fields at specific frequencies (5–15 Hz) activate endogenous opioid (endorphin) release in the spinal dorsal horn and periaqueductal gray, raising the pain threshold and providing analgesic effect independent of uterine activity.

The RCT Evidence

Roozbeh et al. — Double-Blind RCT (n=55)

Women aged 18–30 with confirmed primary dysmenorrhea were randomized to PEMF (5 Hz, 10 mT, 20 minutes, 3 consecutive days per menstrual cycle) or sham. Primary endpoint: VAS pain intensity at 3 cycles.

• PEMF group: VAS 7.4 ± 0.8 → 3.2 ± 0.6 (p<0.001)
• Sham group: VAS 7.3 ± 0.7 → 6.1 ± 0.9
• NSAID consumption: reduced by 68% in the PEMF group vs. 8% in sham
• No adverse events reported in either group

Gharloghi et al. — RCT (n=60)

60 Hz PEMF applied for 30 minutes on each of 3 consecutive menstrual days over 3 cycles.

• Pain intensity reduced by 56% in PEMF group vs. 12% in sham (p<0.01)
• Duration of pain episodes: reduced from 18.4 hours/cycle to 7.2 hours/cycle
• Functional impairment (days absent from work/school): 2.3 → 0.8 days/cycle

Dolatian et al. — RCT (n=42)

60 Hz PEMF, 30 minutes daily for 3 consecutive days during menstruation.

• VAS: 7.1 → 2.3 at 3-month follow-up (p<0.001)
• Systemic symptoms (nausea, headache, fatigue associated with dysmenorrhea): reduced in 78% of PEMF patients

PEMF vs. Conventional Dysmenorrhea Treatments

Clinical Protocol

Session Parameters

• Frequency: 5–60 Hz (lower frequencies for neuromodulation, higher for smooth muscle relaxation)
• Intensity: 10–20 mT
• Duration: 20–30 minutes per session
• Timing: 3 consecutive days beginning on day 1 or at pain onset
• Course: minimum 3 menstrual cycles for cumulative effect

Applicator Placement

• Suprapubic/lower abdominal: primary — over the uterus and adnexa
• Lumbosacral: secondary — over sacral nerve roots (S2–S4) that carry uterine nociceptive fibers
• Combined application (abdominal + sacral): more effective than either alone in two comparative studies

Frequently Asked Questions

Can PEMF be used with an IUD?

Non-hormonal copper IUDs: no contraindication — PEMF does not interact with copper IUDs at standard clinical intensities. Hormonal IUDs (Mirena): the device contains a small amount of metal; discuss with the treating gynaecologist. In practice, most clinicians apply PEMF with hormonal IUDs without incident.

Is PEMF safe in women trying to conceive?

Yes. Unlike NSAIDs (which may affect ovulation at high doses) and hormonal contraceptives (which prevent ovulation), PEMF carries no known fertility-related adverse effects. The field intensities used clinically are far below thresholds associated with any reproductive concern in the peer-reviewed literature.

How many cycles are needed to see sustained results?

Most RCTs show progressive improvement over 3 cycles, with the largest pain reduction occurring between cycles 2 and 3. Patients who respond to PEMF typically maintain benefit for 2–4 months after stopping treatment, though ongoing monthly sessions (3 days per cycle) preserve outcomes.

The Business Case — Women's Health as a High-Margin Service Line

Dysmenorrhea affects 15 million Filipino women — yet physiotherapy clinics have historically captured almost none of this market because conventional physio has no effective protocol for menstrual pain. PEMF changes this: it is the first non-pharmacological device-based intervention with RCT support for dysmenorrhea, creating a new patient segment that can be served at ₱1,500–₱2,500/session for 3 sessions/cycle, generating ₱4,500–₱7,500/month per patient. A clinic managing 20 dysmenorrhea patients/month at ₱6,000 average generates ₱120,000 in incremental monthly revenue from a previously uncaptured population. Across 70+ Israeli clinics (population: 9M) — now expanding to the Philippines — this service line has proven to be among the fastest-growing with minimal marketing spend (patient word-of-mouth drives most referrals).